About

patients’ needs
propel us forward

Our mission & values

We are on a mission to harness the microbiome to transform the lives of patients. To achieve our mission, we have assembled a team of multi-disciplinary experts and built a culture that values collaboration and a diversity of perspectives and ideas. Our team is united by our collective desire to develop a novel class of therapeutics for patients and families battling serious conditions linked to disruption of the microbiome.

Built into our company DNA is a strong commitment to living our core values and utilizing them to guide our decisions and actions.

Patients first

We have an unwavering commitment to putting the needs of patients first in everything we do

Tenacity

We work relentlessly to achieve our mission and deliver on our commitments

Humility

We maintain open minds and constantly work to expand our knowledge

Daring

We push scientific boundaries and ourselves

Community

We are committed to nurturing a strong, diverse community within Finch and giving back to the external communities we are a part of

Our leadership team

Our leadership team is comprised of seasoned biotech executives and recognized leaders in the microbiome field—clinicians and scientists that have paved the way for a new class of therapeutics with the potential to treat a wide range of conditions linked to disruption of the microbiome. Our leadership team combines decades of experience in the areas of microbiology, data science, clinical research, and the manufacture and commercialization of complex biologics.

Card image cap

Mark Smith, PhD

Chief Executive Officer

Card image cap

Greg Perry

Chief Financial Officer

Card image cap

Zain Kassam, MD, MPH

Chief Medical Officer

Card image cap

Michelle Rose, PhD

Chief Regulatory Officer

Card image cap

Andrew Noh

Chief Administrative Officer

Card image cap

Jim Sigler, MBA

Executive Vice President of CMC

Card image cap

Joseph Vittiglio, JD

General Counsel

Card image cap

Kris Piper, MS

Senior Vice President of Regulatory & Quality Assurance

Card image cap

James Burgess

Vice President, Innovation

Card image cap

Sonia Timberlake, PhD

Senior Vice President, Research

Card image cap

Martina Schinke, PhD

Vice President, Program Management

Card image cap

Irina Koroleva, PhD

Vice President, Translational Medicine

Card image cap

David Rhodes, PhD

Vice President, Technical Development

Card image cap

Anne Marie Conway, MHA, RN

Vice President, Clinical Operations

Card image cap

Rozanna Yaing, MBA

Vice President, Quality

Card image cap

Mitch Jones, MD, PHD

Vice President, Clinical Discovery and Development

Card image cap

David Pugatch, MD

Vice President, Clinical Development

Our board of directors

Our Collaborators

We believe that collaboration is key to unlocking the full potential of the microbiome. As such, we have partnerships with leading clinician researchers and institutions driving human microbiome research around the globe—from the United States to Australia and China.

We are also proud to partner with Takeda Pharmaceuticals on the development of microbiome drugs for individuals with ulcerative colitis and Crohn’s disease, the most common types of inflammatory bowel disease (IBD). Our partnership, initially focused on the development of FIN-524 for ulcerative colitis, was expanded in 2019 to include the initial development of a potential microbiome product candidate, FIN-525, for Crohn’s disease. Takeda’s deep expertise in gastroenterology and IBD is an ideal complement to our own expertise in microbiome therapeutics.

Collaborate with us

We actively partner with academic researchers to catalyze discoveries in the microbiome. Please reach out to us if you would like to explore opportunities to work together.

Contact us

To read more about our collaboration with Takeda:

Takeda

Finch Therapeutics & Takeda Expand Collaboration to Develop Microbiome Therapeutics Using Finch’s Human-First Discovery Platform

2019

Finch Therapeutics and Takeda Announce Global Collaboration to Develop Microbiome Therapeutics in Inflammatory Bowel Disease

2017

Contact us

General inquiries:

[email protected]

Collaborations:

[email protected]

Investor inquiries:

[email protected]

Media inquiries:

[email protected]

Our office:

200 Inner Belt Road, Suite 400
Somerville, MA, 02143
T: 617-229-6499

Follow us